Mark L. Baum
Known title: Chief Executive OfficerCIK: 0001274282
Mark L. Baum's purchase track record
How the stock did after each of Mark L. Baum's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
4
of 5 since December 22, 2022
Stock higher 6 months later
75%
3 months: 80%
Median 6-month return
+62.6%
3 months: +27.9%
Beat the S&P 500
75%
median +46.5% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/14/2026 | HROW | $302K | +26.0% | pending | — |
| 3/22/2024 | HROW | $104K | +82.6% | +291.5% | +8.9% |
| 11/16/2023 | HROW | $61K | +29.1% | +87.9% | +17.5% |
| 8/14/2023 | HROW | $99K | -25.8% | -32.2% | +11.8% |
| 12/22/2022 | HROW | $335K | +27.9% | +37.3% | +14.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| HROW | ▲ Buy | Open Market | 10,000 | $302K | 5/14/2026 | View on chart |
| HROW | ▲ Buy | Option Exercise | 180,000 | $711K | 12/12/2025 | View on chart |
| HROW | ▼ Sell | Tax Withholding | 79,994 | $3.8M | 12/12/2025 | View on chart |
| HROW | ▲ Buy | Option Exercise | 600,000 | $4.7M | 7/21/2025 | View on chart |
| HROW | ▼ Sell | Tax Withholding | 313,338 | $11.6M | 7/21/2025 | View on chart |
| HROW | ▼ Sell | Tax Withholding | 300,363 | $6.9M | 4/7/2025 | View on chart |
| HROW | ▲ Buy | Option Exercise | 762,300 | $0 | 4/3/2025 | View on chart |
| HROW | ▲ Buy | Open Market | 9,000 | $104K | 3/22/2024 | View on chart |
| HROW | ▲ Buy | Option Exercise | 150,000 | $1.6M | 2/20/2024 | View on chart |
| HROW | ▲ Buy | Option Exercise | 59,836 | $638K | 2/20/2024 | View on chart |
| HROW | ▲ Buy | Option Exercise | 15,400 | $119K | 2/7/2024 | View on chart |
| HROW | ▲ Buy | Open Market | 7,500 | $61K | 11/16/2023 | View on chart |
| HROW | ▲ Buy | Open Market | 5,800 | $99K | 8/14/2023 | View on chart |
| HROW | ▼ Sell | Tax Withholding | 299,968 | $5.5M | 7/18/2023 | View on chart |
| HROW | ▲ Buy | Option Exercise | 762,300 | — | 7/18/2023 | View on chart |
| HROW | ▲ Buy | Option Exercise | 180,000 | $1.6M | 4/3/2023 | View on chart |
| HROW | ▼ Sell | Tax Withholding | 117,633 | $2.5M | 4/3/2023 | View on chart |
| HROW | ▲ Buy | Option Exercise | 88,000 | — | 1/2/2023 | View on chart |
| HROW | ▼ Sell | Tax Withholding | 35,179 | $519K | 1/2/2023 | View on chart |
| HROW | ▲ Buy | Open Market | 25,000 | $335K | 12/22/2022 | View on chart |
| HROW | ▲ Buy | Option Exercise | 125,000 | $300K | 1/20/2022 | View on chart |
| HROW | ▼ Sell | Tax Withholding | 71,406 | $595K | 1/20/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Harrow (HROW) gains analyst support and conference buzz amid turnaround focus
Recent coverage highlights growing attention on Harrow’s ophthalmic pipeline, with analysts maintaining a $63 price target and an average target of $65. A recent conference has generated buzz, while options activity suggests market participants are watching the stock closely. The company’s Q3 results are expected to confirm whether the turnaround plan is taking hold.
Harrow (HROW) gains analyst support and conference buzz amid turnaround focus. Recent coverage highlights growing attention on Harrow’s ophthalmic pipeline, with analysts maintaining a $63 price target and an average target of $65. A recent conference has generated buzz, while options activity suggests market participants are watching the stock closely. The company’s Q3 results are expected to confirm whether the turnaround plan is taking hold.